No connection

Search Results

EVH vs SLN

EVH
Evolent Health, Inc.
BEARISH
Price
$3.13
Market Cap
$349.4M
Sector
Healthcare
AI Confidence
85%
SLN
Silence Therapeutics plc
BEARISH
Price
$7.53
Market Cap
$355.7M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
EVH
--
SLN
--
Forward P/E
EVH
7.09
SLN
-10.46
P/B Ratio
EVH
0.84
SLN
5.71
P/S Ratio
EVH
0.19
SLN
636.26
EV/EBITDA
EVH
13.46
SLN
-12.02

Profitability

Gross Margin
EVH
21.31%
SLN
61.54%
Operating Margin
EVH
-2.06%
SLN
-37150.0%
Profit Margin
EVH
-28.49%
SLN
0.0%
ROE
EVH
-66.54%
SLN
-90.27%
ROA
EVH
-0.12%
SLN
-30.79%

Growth

Revenue Growth
EVH
-27.5%
SLN
-99.9%
Earnings Growth
EVH
--
SLN
--

Financial Health

Debt/Equity
EVH
2.38
SLN
0.0
Current Ratio
EVH
1.31
SLN
8.72
Quick Ratio
EVH
1.2
SLN
8.06

Dividends

Dividend Yield
EVH
--
SLN
--
Payout Ratio
EVH
0.0%
SLN
0.0%

AI Verdict

EVH BEARISH

EVH exhibits severe fundamental deterioration, highlighted by a weak Piotroski F-Score of 2/9 and a significant YoY revenue decline of 27.50%. While the stock trades at a low Price-to-Book (0.84) and Price-to-Sales (0.19) ratio, these metrics likely represent a value trap given the negative profit margins (-28.49%) and high debt-to-equity ratio (2.38). Despite a 'Strong Buy' analyst consensus and a target price of $5.18, the deterministic data and long-term price performance (-85.2% over 5 years) suggest a high-risk profile with failing operational momentum.

Strengths
Low Price-to-Sales ratio (0.19) suggests extreme undervaluation relative to revenue
Trading below book value (P/B 0.84)
Current ratio of 1.31 indicates adequate short-term liquidity
Risks
Severe revenue contraction (-27.50% YoY)
Poor financial health as evidenced by Piotroski F-Score of 2/9
High leverage with a Debt/Equity ratio of 2.38
SLN BEARISH

SLN exhibits severe fundamental distress, highlighted by a Piotroski F-Score of 1/9, indicating critical financial weakness. The company has experienced a catastrophic revenue collapse of -99.90% YoY, rendering traditional valuation metrics like the P/S ratio (636.26) meaningless. While the current ratio of 8.72 suggests a temporary liquidity cushion, the operating margin of -37,150% and negative ROE of -90.27% signal an unsustainable burn rate. The recent price surge is entirely decoupled from financial performance and appears purely speculative.

Strengths
High current ratio (8.72) providing short-term liquidity
Zero debt (Debt/Equity 0.00) reducing insolvency risk from leverage
Positive gross margin (61.54%) suggesting potential for product viability
Risks
Near-total collapse of revenue (-99.90% YoY)
Extreme operational inefficiency (Operating Margin -37,150%)
Critical financial health score (Piotroski 1/9)

Compare Another Pair

EVH vs SLN: Head-to-Head Comparison

This page compares Evolent Health, Inc. (EVH) and Silence Therapeutics plc (SLN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile